Capricor Therapeutics (CAPR) Assets Average (2011 - 2026)

Capricor Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $341.1 million for Q1 2026.

• On a quarterly basis, Assets Average rose 110.41% year-over-year to $341.1 million in Q1 2026; TTM through Mar 2026 was $341.1 million, a 110.41% increase from a year earlier, with the FY2025 full-year figure at $263.2 million, up 129.67% from the prior year.
• Assets Average climbed to $341.1 million in Q1 2026 per CAPR's latest filing, from $241.2 million in the prior quarter.
• Across five years, Assets Average topped out at $341.1 million in Q1 2026 and bottomed at $41.6 million in Q3 2023.
• The 5-year median for Assets Average is $56.0 million (2022), against an average of $101.6 million.
• Across the five-year window, Assets Average retreated 25.74% in 2023 and soared 227.55% in 2025, its largest moves.
• Year by year, Assets Average stood at $52.0 million in 2022, then decreased by 7.82% to $47.9 million in 2023, then surged by 174.73% to $131.7 million in 2024, then surged by 83.12% to $241.2 million in 2025, then surged by 41.43% to $341.1 million in 2026.
• Per Business Quant, the three latest CAPR Assets Average figures stand at $341.1 million (Q1 2026), $241.2 million (Q4 2025), and $130.0 million (Q3 2025).